Format

Send to

Choose Destination
HIV Clin Trials. 2018 Feb;19(1):8-14. doi: 10.1080/15284336.2017.1411419. Epub 2017 Dec 21.

Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials.

Author information

1
a Department of Obstetrics and Gynaecology , College of Health Sciences, University of Zimbabwe , Harare , Zimbabwe.
2
b UZ-UCSF Women's Collaborative Research Programme , Harare , Zimbabwe.
3
c Department of Epidemiology , Johns Hopkins University , Baltimore , MD , USA.
4
d Vaccine and Infectious Disease Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
5
e Department of Epidemiology , University of Washington , Seattle , WA , USA.
6
f Department of Global Health , University of Washington , Seattle , WA , USA.
7
g Department of Obstetrics and Gynaecology , Makerere University - Johns Hopkins University , Uganda.
8
h FHI 360 , Durham , NC , USA.
9
i Division of AIDS , National Institutes of Health (NIH) , Rockville , MD , USA.
10
j US Department of State , Washington , DC , USA.
11
k Department of Biostatistics , University of Washington , Seattle , WA , USA.
12
l Department of OB/GYN/RS , Magee-Womens Hospital of UPMC , Pittsburgh , PA , USA.

Abstract

BACKGROUND:

Safety data on pregnancy and fetal outcomes among women in HIV prevention trials are urgently needed to inform use of effective antiretroviral agents for HIV prevention. We describe an effective, efficient, and novel method to prospectively collect perinatal safety data concurrent with on-going parent clinical trials.

METHODS:

The Microbicide Trials Network (MTN)-016 study is a multinational prospective pregnancy exposure registry designed to capture pregnancy and neonatal outcomes. Studies currently contributing data to this registry included phase I and II safety trials with planned exposures to candidate HIV prevention agents, as well as phase IIB and III efficacy trials capturing data on pregnancy and infant outcomes following inadvertent fetal exposure during study participation.

RESULTS:

To date, participants from two phase I studies and two effectiveness trials have participated in MTN-016, resulting in 420 pregnant women and 381 infants enrolled. Infant retention has been high, with 329 of 381 (86%) infants completing the 12-month follow-up visit.

CONCLUSION:

In a research setting context, it is feasible to establish and implement a prospective, multinational HIV chemoprophylaxis pregnancy registry that will generate pregnancy exposure data in a robust fashion.

KEYWORDS:

ARV-chemoprophylaxis agents; HIV; congenital malformation; pregnancy; registry

PMID:
29268654
PMCID:
PMC5995113
DOI:
10.1080/15284336.2017.1411419
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center